Should patients with locally advanced, non-metastatic carcinoma of the pancreas be irradiated?

Pancreatology

Volumn 3, Issue 5, 2003, Pages 359-366

  Wenz, Frederik ^a,c   Tiefenbacher, Uta ^a   Fuss, Martin ^b   Lohr, Frank ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Combined modality; Locally advanced pancreatic carcinoma; Pancreatic carcinoma; Radiotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; PACLITAXEL;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; MEDICAL LITERATURE; NONSURGICAL INVASIVE THERAPY; PANCREAS CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SIDE EFFECT; SURVIVAL RATE; TOXICITY;

EID: 0242460555     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000073650     Document Type: Review

References (64)

1. Gastrointestinal Tumor Study Group: A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. Ann Surg 1979;189:205-208.
2. Gastrointestinal Tumor Study Group: Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 1985;56:2563-2568.
3. Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-755.
4. Gastrointestinal Tumor Study Group: Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic carcinoma. Int J Radiat Oncol Biol Phys 1979;5:1643.
5. Gastrointestinal Tumor Study Group: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high-dose (6,000 rads) radiation alone, moderate dose radiation (4,000 rads + 5-fluorouracil), and high-dose radiation + 5-fluorouracil. Cancer 1981;48:1705-1710.
6. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;ii:865-867.
7. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG: Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - An Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373-378.
8. Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, Norris BD, Kardinal CG, Tschetter LK, Barlow JF: A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin and cisplatin. Cancer 1990;65:2207-2212.
9. Komaki R, Wadler S, Peters T, et al: High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. A preliminary report of a multi-institutional trial (Radiation Therapy Oncology Group protocol 8801). Cancer 1992;69:2807-2812.
10. Mohiuddin M, Cantor RJ, Biermann W, et al: Combined modality treatment of localized unresectable adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1987;14:79.
11. Seydel HG, Stablein DM, Leichman LP, et al: Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience. Cancer 1990;65:1478-1482.
12. Whittington R, Dobelbower RR, Mohiuddin M, et al: Radiotherapy of unresectable pancreatic carcinoma: A six-year experience with 104 patients. Int J Radiat Oncol Biol Phys 1981;7:1639.
13. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-3275.
14. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA: A double-blind, placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first-line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-167.
15. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Stornioli AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
16. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94:902-910.
17. Ducreux M, Rougier P, Pignon JP, Douillard JY, Seitz JF, Bugat R, Bosset JF, Merouche Y, Raoul JL, Ychou M, Adenis A, Berthault-Cvitkovic F, Luboinski M: A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002;13:1185-1191.
18. Heinemann V, Wilke H, Mergenthaler HG, Clemens M, Konig H, Illiger HJ, Arning M, Schalhorn A, Possinger K, Fink U: Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000;11:1399-1403.
19. Huguier M, Barrier A, Valinas R, Flahault A, Adloff M, Pezet D, Jaeck D, Millat B: Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer. Hepatogastroenterology 2001;48:875-878.
20. Johnson CD, Puntis M, Davidson N, Todd S, Bryce R: Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma. Br J Surg 2001;88:662-668.
21. Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R: A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 1991;68:965-969.
22. Louvet C, Andre T, Hammel P, Selle F, Landi B, Cattan S, Fonck M, Flesch M, Colin P, Balosso J, Ruszniewski P, de Gramont A: Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol 2001;12:675-679.
23. Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002;20:1512-1518.
24. Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, Iveson T, O'Brien M, Tebbutt N, Harrington A, Hill M: Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002;20:3130-3136.
25. Marantz A, Jovtis S, Almira E, Balbiani L, Castilla JL, Fein L, Lewi D, Pasccon G, Pinckevicius R, Uranga G, Abal M, Muino M, Reale M, Agusto S: Phase II study of gemcitabine, 5-fluorouracil and leucovorin in patients with pancreatic cancer. Semin Oncol 2001;28(suppl 10):44-49.
26. Reni M, Passoni P, Panucci MG, Nicoletti R, Galli L, Balzano G, Zerbi A, Di Carlo V, Villa E: Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 2001;19:2679-2686.
27. Neri B, Cini G, Doni L, Fulignati C, Turrini M, Pantalone D, Mini E, De Luca Cardillo C, Fioretto LM, Ribecco AS, Moretti R, Scatizzi M, Zocchi G, Quattrone A: Weekly gemcitabine plus epirubicin as effective chemotherapy for advanced pancreatic cancer: A multicenter phase II study. Br J Cancer 2002;87:497-501.
28. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC: Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81:882-885.
29. Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D, Shields AF: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001;92:569-577.
30. Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002;20:1182-1191.
31. Rocha Lima CM, Urbanic JJ, Lal A, Kneuper-Hall R, Brunson CY, Green MR: Beyond pancreatic cancer: Irinotecan and gemcitabine in solid tumors and hematologic malignancies. Semin Oncol 2001;28(suppl 10):34-43.
32. Ceha HM, van Tienhoven G, Gouma DJ, Veenhof CH, Schneider CJ, Rauws EA, Phoa SS, Gonzalez Gonzalez D: Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 2000;89:2222-2229.
33. Higgins D, Sohn JW, Fine RM, Schell MC: Three-dimensional conformal pancreas treatment: Comparison of four- to six-field techniques. Int J Radiat Oncol Biol Phys 1995;31:605-609.
34. Robertson JM, Marsh L, TenHaken RK, Lawrence TS: The clinical application of a non-axial treatment plan for pancreatic and biliary malignancies. Radiother Oncol 1992;24:198-200.
35. Tisdale BA, Paris KJ, Lindberg RD, Jose B, Spanos WJ: Radiation therapy for pancreatic cancer: A retrospective study of the University of Louisville experience. South Med J 1995;88:741-744.
36. Shinchi H, Takao S, Noma H, Matsuo Y, Mataki Y, Mori S, Aikou T: Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002;53:146-150.
37. Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997;79:1516-1520.
38. Kachnic LA, Shaw JE, Manning MA, Lauve AD, Neifeld JP: Gemcitabine following radiotherapy with concurrent 5-fluorouracil for non-metastatic adenocarcinoma of the pancreas. Int J Cancer 2001;96:132-139.
39. Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T: A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2002;86:1551-1554.
40. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, Lawrence TS: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202-4208.
41. Fisher BJ, Perera FE, Kocha W, et al: Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1999;45:291-295.
42. Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA: Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002;52:1293-1302.
43. Poen JC, Collins HL, Niederhuber JE, et al: Chemoradiotherapy for localized pancreatic cancer: Increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouacil. Int J Radiat Oncol Biol Phys 1998;40:93-99.
44. Boz G, De Paoli A, Innocente R, Rossi C, Tosolini G, Pederzoli P, Talamini R, Trovo MG: Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2001;51:736-740.
45. Mehta VK, Poen JC, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, Fisher GA: Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol 2001;24:155-159.
46. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB 3rd: Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity. J Clin Oncol 2000;18:3384-3389.
47. Whittington R, Neuberg D, Tester WJ, Benson AB 3rd, Haller DG: Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: A phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol 1995;13:227-232.
48. Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong A, Phan T, Nguyen Q, Abbruzzese JL: Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 2001;29:9-18.
49. De Lange SM, van Groeningen CJ, Meijer OW, Cuesta MA, Langendijk JA, van Riel JM, Pinedo HM, Peters GJ, Meijer S, Slotman BJ, Giaccone G: Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 2002;38:1212-1217.
50. Epelbaum R, Rosenblatt E, Nasrallah S, Faraggi D, Gaitini D, Mizrahi S, Kuten A: Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 2002;81:138-143.
51. Pipas JM, Mitchell SE, Barth RJ Jr, Vera-Gimon R, Rathmann J, Meyer LP, Wagman RS, Lewis LD, McDonnell C, Colacchio TA, Perez RP: Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2001;50:1317-1322.
52. Poggi MM, Kroog GS, Russo A, Muir C, Cook J, Smith J, Mitchell JB, Herscher LL: Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002;54:670-676.
53. Safran H, Dipetrillo T, Iannitti D, Quirk D, Akerman P, Cruff D, Cioffi W, Shah S, Ramdin N, Rich T: Gemcitabine, paclitaxel and radiation for locally advanced pancreatic cancer: A phase I trial. Int J Radiat Oncol Biol Phys 2002;54:137-141.
54. Wiegel T, Runkel N, Frommhold H, Rube C, Hinkelbein W: Radiotherapeutic strategies in the multimodal therapy of resectable and non-resectable pancreatic carcinoma. Strahlenther Onkol 2000;176:299-306.
55. Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL: Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 2001;7:2246-2253.
56. Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber KJ: Radiosensitizing potential of gemcitabine (2′2′-difluoro-2′- deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 1998;41:875-882.
57. Lawrence TS, Davis MA, Hough A, Rehemtulla A: The role of apoptosis in 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res 2001;7:314-319.
58. Milas L, Fujii T, Hunter N, et al: Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107-114.
59. Mason KA, Milas L, Hunter NR, et al: Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 1999;44:1125-1135.
60. Safran H, Moore T, Iannitti D, Dipetrillo T, Akerman P, Cioffi W, Harrington D, Quirk D, Rathore R, Cruff D, Vakharia J, Vora S, Savarese D, Wanebo H: Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2001;49:1275-1279.
61. Azria D, Ychou M, Jacot W, Thezenas S, Lemanski C, Senesse P, Prost P, Delard R, Masson B, Dubois JB: Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas 2002;25:360-365.
62. Carraro S, Roca EL, Cartelli C, Rafailovici L, Castillo Odena S, Wasserman E, Gualdrini U, Huertas E, Barugel M, Ballarino G, Rodriguez MC, Masciangioli G: Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: A phase II IATTGI study. Int J Radiat Oncol Biol Phys 2002;54:397-402.
63. Okusaka T, Okada S, Tokuuye K, Wakasugi H, Saisho H, Ishikawa O, Matsuno S, Sato T, Sato K: Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. Cancer 2001;91:1384-1389.
64. Prott FJ, Schoenekäs K, Preusser P, et al: Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: Results of a feasibility study. Br J Cancer 1997;75:597-601.